Top in endocrinology: Omnipod 5 for type 2 diabetes; single-dose vials of tirzeptaide

The FDA has cleared a tubeless automated insulin delivery system indicated for adults with type 2 diabetes.

This new indication for the Omnipod 5 (Insulet) makes it the first automated insulin delivery system available for both type 1 and type 2 diabetes in the U.S., according to a company press release.

“Omnipod 5 makes it easier for people with type 2 diabetes to take their insulin and stay in range, leading to remarkable improvements in clinical outcomes and overall quality of life,” Anne L. Peters, MD, a Healio | Endocrine Today Editorial Board member, professor of clinical medicine at the University of Southern California Keck School of Medicine and director of the University of Southern California Westside Center for Diabetes, said in the release. “I believe this innovative technology has the potential to transform the lives of insulin-requiring people with type 2 diabetes.”

It was the top story in endocrinology last week.

In another top story, adults with obesity who have been prescribed tirzepatide (Zepbound, Eli Lilly) can now purchase 2.5 mg and 5 mg single-dose vials of the medication through a self-pay pharmacy component of the manufacturer’s digital health care hub LillyDirect.

Read these and more top stories in endocrinology below:

FDA clears tubeless automated insulin delivery system for adults with type 2 diabetes

The FDA has approved expanded use of an automated insulin delivery system to include adults with type 2 diabetes, Insulet Corp. announced. Read more.

Single-dose vials of tirzepatide now available on LillyDirect for adults with obesity

Adults with obesity who have been prescribed tirzepatide can now purchase 2.5 mg and 5 mg single-dose vials of the medication, Eli Lilly announced. Read more.

Personal CGM use in hospitals feasible, preferred by nurses and patients

A change to hospital policy allowing patients to use their own continuous glucose monitors instead of finger-stick blood glucose monitoring was met favorably by a majority of patients and nurses, according to study findings. Read more.

SGLT2 inhibitors tied to similar dementia risk as dulaglutide in type 2 diabetes

SGLT2 inhibitors and dulaglutide confer a similar risk for dementia among adults aged 60 years and older with type 2 diabetes, according to findings published in Annals of Internal Medicine. Read more.

Less than 1% of Military Health System beneficiaries use an obesity medication

Obesity medications were prescribed to very few Military Health System beneficiaries between October 2017 and September 2022, according to a study published in Obesity. Read more.